New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:37 EDTQCOR, TSLA, KMI, PBR, AAPL, C, BIDU, TEVAActive equity options trading on open Teva
Active equity options trading on open according to Track Data: AAPL TSLA BIDU PBR QCOR C KMI TEVA
News For AAPL;TSLA;BIDU;PBR;QCOR;C;KMI;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
February 17, 2015
13:18 EDTAAPLOmega Advisors gives quarterly update on stakes
Subscribe for More Information
12:50 EDTAAPLOn The Fly: Midday Wrap
Subscribe for More Information
10:31 EDTAAPL, TSLAApple rises as analysts applaud reported auto ambitions
Subscribe for More Information
09:40 EDTAAPL, C, BIDU, TSLAActive equity options trading on open
Subscribe for More Information
08:47 EDTTEVABioTime provides update on Cell Cure's product development, partnering
BioTime (BTX) and its subsidiary Cell Cure Neurosciences provided an update on Cell Cure’s product development and partnering activities. On February 16, Cell Cure opened the clinical trial of OpRegen titled “Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy” at Hadassah University Medical Center in Jerusalem, Israel. Patient enrollment is expected to begin shortly. OpRegen consists of animal product-free retinal pigment epithelial cells with high purity and potency. On October 31, 2014, the FDA cleared Cell Cure's Investigational New Drug application to initiate the clinical trial of OpRegen in patients with the severe form of age-related macular degeneration with geographic atrophy.The Phase I/IIa clinical trial, will evaluate three different dose regimens of OpRegen. Following transplantation, the patients will be followed for 12 months at specified intervals, to evaluate the safety and tolerability of the product. Following the initial 12 month period, patients will continue to be monitored at longer intervals for an additional period of time. A secondary objective of the clinical trial will be to examine the ability of transplanted OpRegen to engraft, survive, and moderate disease progression in the patients. In addition to thorough characterization of visual function, a battery of ophthalmic imaging modalities will be used to quantify structural changes and rate of GA expansion. Cell Cure also announced that the option granted to Teva (TEVA) under a Research and Exclusive Option Agreement of October 7, 2010 to license-in rights to its OpRegen product has expired without having been exercised by Teva. Cell Cure will therefore be continuing the clinical development of OpRegen on its own and pursuing discussions with other potential strategic partners, including those that have already indicated interest in participating in development and commercialization of the product. Cell Cure also announced that US patent No. 8,956,866 relating to a proprietary method of manufacturing RPE cells is expected to issue on February 17. This patent combined with other patents and patent applications in the BioTime family of companies provides significant patent protection for this novel therapeutic modality for AMD.
08:39 EDTTEVATeva deal small but important, says BMO Capital
Subscribe for More Information
08:35 EDTTEVATeva announces launch of generic Lovenox and Zyvox in U.S.
Subscribe for More Information
08:04 EDTCWuXi PharmaTech enters into loan agreement with consortium led by Citi
Subscribe for More Information
07:32 EDTAAPLApple asking suppliers to make 5M-6M Apple Watches in Q1, WSJ says
Subscribe for More Information
07:28 EDTAAPLApple design chief working on store redesign ahead of Watch, New Yorker says
Subscribe for More Information
07:22 EDTAAPLMitsubishi UFJ to hold a tour
Subscribe for More Information
07:15 EDTAAPLApple foray into autos would be logical, says Barclays
Subscribe for More Information
07:08 EDTAAPLAuto market could be meaningful for Apple, says Cantor
Subscribe for More Information
07:04 EDTTEVATeva, Eagle enter license agreement for EP-3102
Teva Pharmaceutical Industries (TEVA) and Eagle Pharmaceuticals (EGRX) announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle’s bendamustine hydrochloride rapid infusion product for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva. As part of the agreement, Teva will waive its orphan drug exclusivities for NHL and CLL with respect to EP-3102, which should allow the product to come to market more quickly. Under the terms of the exclusive license agreement, Eagle will receive an upfront cash payment of $30M and is eligible to receive up to $90M in additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming FDA approval. The companies will also settle the pending patent infringement action between them.
06:39 EDTCBanks settle claims related to mortgage securities, Reuters says
Subscribe for More Information
06:20 EDTPBRRolls-Royce vows to cooperate with Petrobras investigation, Financial Times says
Rolls-Royce (RYCEY) said it will co-operate with Brazilian authorities investigating allegations that it paid bribes to win a contract from Petrobras (PBR), reports the Financial Times. The company said, “We will take all necessary action to ensure compliance, including co-operating with authorities in any country.” Rolls-Royce had been accused of paying bribes in exchange for a $100M contract to provide “modules of energy generation” for the oil company’s platforms. Reference Link
February 15, 2015
16:44 EDTAAPLApple Watch could increase revenue by 10% next year, Barron's says
Subscribe for More Information
15:51 EDTPBRBrazil's tax watchdog opens probe into Petrobras, HSBC link, Reuters says
Subscribe for More Information
07:47 EDTAAPLHope of car positive for Apple shares, says Piper Jaffray
Piper Jaffray analyst Gene Munster said in a note to investors yesterday that the potential for a car gives investors something to look at as "the next big thing" for Apple. Munster believes the Wall Street Journal's report that Apple is building an electric car will help support the stock over the next six months. He believes it is unlikely that the company launches anything in the next five years, however. Munster reiterated an Overweight rating on Apple with a $160 price target. The stock closed Friday up 62c to $127.08.
07:46 EDTAAPLApple working on minivan-like electric vehicle, WSJ reports
Apple has "several hundred" employees working secretly toward creating an Apple-branded electric vehicle, Wall Street Journal reported yesterday, citing people familiar with the matter. The project is known internally as "Titan" and has a design that resembles a minivan, the Journal added. The Financial Times reported yesterday that the iPhone maker is recruiting experts in automotive technology and vehicle design. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use